Advertisement

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement

Jul

17

Today In Oncology

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

Study Finds Rising Breast Cancer Incidence Across Asian American, Native Hawaiian, and Pacific Islander Groups

Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors

ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases

Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes

Advertisement

© 2026 HSP News Service, L.L.C.